

PA MEDTECH VENTURE CAPITAL FUND

Webinar – Get to know the companies
we invest in

May 2022



Fund
Launched!
November 17th, 2021

01

Intro Shifamed

02

Shifamed Process

03

Deep Dive Portfolio Companies

04

How does the current market environment impact Shifamed portfolio companies?


05

Q&A



01 Intro Shifamed

Shifamed in Numbers



Founded in
2007



Around 200
Employees



Currently 7 Portfolio
Companies



6 out of 6
Successful Exits








02

Shifamed Process

03

Deep Dive Portfolio Companies

Anticipated Portfolio Company Financings

Status	Company	Description
Invested in December 2021	 AKURA MEDICAL	Thrombectomy device to efficiently remove blood clots in a single pass
Investment planned in the summer 2022	 ATIA VISION TRULY INSIGHTFUL	Modular accommodating IOL that is adjustable post-implant
Pipeline	 Enlil	Cloud-based enterprise software to automate quality documentation & business processes
Invested in February 2022	 Supira MEDICAL	Percutaneous heart pump for high-risk PCI & cardiogenic shock patients. Short term use, no longer than ~14 days
Invested in April 2022	 Adona MEDICAL	Heart failure shunt with differentiated novel key feature
Pipeline	 MYRA MEDICAL	Glaucoma shunt with titratable flow
Pipeline	 TIOGA MEDICAL	Transseptal approach for mitral / tricuspid valve replacement



Status	Description	Current status & expected upcoming events	Current employees	Earliest possible exit	Financing to date	Projected next Round
Invested in December 2021	Thrombectomy device to efficiently remove blood clots in a single pass	► Early prototype phase	4	2023	\$27M	Q2 2023 ~25M



Status	Description	Current status & expected upcoming events	Current employees	Earliest possible exit	Financing to date	Projected next Round
Invested in February 2022	Percutaneous heart pump for high-risk PCI & cardiogenic shock patients. Short term use, no longer than ~14 days	► FIH to start in Q2 2022	48	2022	\$111.1M	-

Adona

MEDICAL

Status	Description	Current status & expected upcoming events	Current employees	Earliest possible exit	Financing to date	Projected next Round
Invested in April 2022	Heart failure shunt with differentiated novel key feature	► Pre-clinical development phase	22	2024	\$63.4M	Q3 2023 \$30-35M



Status	Description	Current status & expected upcoming events	Current employees	Earliest possible exit	Financing to date	Projected next Round
Investment planned in the summer 2022	Modular accommodating IOL that is adjustable post-implant	► Clinical feasibility study Q4 2021	20	2022	\$37M	Q2 2022 ~\$30-35M



Status	Description	Current status & expected upcoming events	Current employees	Earliest possible exit	Financing to date	Projected next Round
Pipeline	Transseptal approach for mitral /tricuspid valve replacement	► Pre-clinical development phase	28	2023	\$48M	Q1 2023 ~\$30-40M

404

How does the current market environment impact Shifamed portfolio companies?

Save the Date

MedTech VC Fund 2nd Closing

June 2022

Fact Sheet

Fund
Launched!
November 17th, 2021

Picard Angst	Picard Angst MEDTECH
Type of Investors	Professional/Institutional clients
Fund Size	50-100 m USD (First Close: 20.75 m USD)
Minimum Investment	150 k USD
Management Fee	2% p.a.
Performance Fee	20%
Investment Criteria	Big medical device market / fast follower opportunity
Stage	Early stage / Pre-revenue
Fund Life	5 years + 1 + 1
Investment Manager	Picard Angst Ltd.
Fund Administrator	Notz Stucki (Lux)
Fund Custodian	UBS
Legal Structure	Reserved Alternative Investment Fund (RAIF)
Marketing Authorization	Authorized for Institutional investors in Luxembourg, Switzerland and EU (Specific jurisdictions to be approved on demand)



PICARD ANGST